

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2025-26

Date: 13.02.2026

BSE Limited 25th Floor Phiroze Jeebhoy Towers Dalal Street, Mumbai 400 001  BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051  NSE Code: MEDICAMEQ
--	--

**Sub. : Outcome of Board Meeting**

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, were approved by the Board of Directors of the Company at its meeting held today at 2.30 P.M. and concluded at 03.45 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- a) The Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025; as **(Annexure- A)**
- b) Limited Review Reports from Rai Qimat & Associates, Chartered Accountants on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter as **(Annexure- B)**
- c) Take note of Completion of Tenure / Cessation of Independent Directors Mr. Harish Pande (DIN: 01575625) and Mr. Arun Kumar (DIN: 07031730), shall cease to be an Independent Directors of the Company upon completion of 2 consecutive terms of 5 years each at the closure of business hours on 13<sup>th</sup> February 2026.
- d) **Reconstitution of Committees**  
In view of the above completion of tenure of Directorship, the Board approved reconstitution of following committees with effect from 13<sup>th</sup> February 2026:
  - a) Audit Committee
  - b) Stakeholders Relationship Committee
  - c) Nomination and Remuneration Committee
  - d) Risk Management Committee
  - e) Corporate Social Responsibility Committee



We request you to take the same on record.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2025, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,  
For Medicamen Biotech Limited

  
  
Parul Choudhary  
Company Secretary  
ACS44157

PARUL  
CHOUDHARY  
RY

Digitally signed by  
PARUL  
CHOUDHARY  
Date: 2026.02.13  
15:52:23 +05'30'



## MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 31st Dec'2025

### PART I

Particulars	Standalone						Consolidated					
	Three Month period Ended			Nine Months Ended		Year Ended	Three Month period Ended			Nine Months Ended		Year Ended
	31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 Audited	31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 Audited
<b>1</b> Income from operations												
(a) Net Sales / Income from operations	4,349.07	4,222.52	4,114.23	12,416.50	12,546.79	15,146.33	4,690.85	4,716.98	4,514.22	13,712.31	13,293.42	16,254.72
(b) Other Income	53.49	37.28	14.08	137.80	100.56	622.51	53.49	37.28	14.07	137.80	101.66	624.39
(c) Total Revenue	<b>4,402.57</b>	<b>4,259.80</b>	<b>4,128.30</b>	<b>12,554.30</b>	<b>12,647.34</b>	<b>15,768.85</b>	<b>4,744.34</b>	<b>4,754.26</b>	<b>4,528.29</b>	<b>13,850.11</b>	<b>13,395.08</b>	<b>16,879.10</b>
<b>2</b> Expenses												
a) Cost of Material Consumed	2,124.86	2,125.61	2,787.80	6,638.26	7,792.29	8,883.33	2,168.63	2,197.18	2,852.24	6,825.58	7,913.25	9,064.97
b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
c) Changes in inventory of Finished Goods and Work in Progress	202.33	118.13	(608.98)	131.97	(821.62)	(608.08)	202.33	118.13	(620.17)	131.97	(827.90)	(603.17)
d) Employees Benefits Expenses	552.89	571.22	544.07	1,654.64	1,604.74	2,157.02	837.29	883.08	800.49	2,529.40	2,347.47	3,187.29
e) Finance Cost	78.20	84.12	73.25	218.56	242.27	304.54	97.20	98.89	75.95	311.44	250.62	315.61
f) Depreciation and Amortisation Expenses	175.03	181.04	217.26	533.37	648.69	696.21	182.74	185.67	220.97	548.53	658.73	706.61
g) Other expenses	961.11	902.91	767.14	2,575.67	2,206.27	3,058.38	1,045.07	1,003.02	811.12	2,810.72	2,313.95	3,219.80
<b>Total Expenses</b>	<b>4,094.43</b>	<b>3,983.04</b>	<b>3,780.53</b>	<b>11,752.46</b>	<b>11,672.63</b>	<b>14,491.41</b>	<b>4,533.26</b>	<b>4,485.97</b>	<b>4,140.59</b>	<b>13,157.64</b>	<b>12,656.11</b>	<b>15,891.10</b>
<b>3</b> Profit/(Loss) before Exceptional Items & Tax (1 - 2)	<b>308.14</b>	<b>276.76</b>	<b>347.77</b>	<b>801.83</b>	<b>974.71</b>	<b>1,277.44</b>	<b>211.09</b>	<b>268.29</b>	<b>387.70</b>	<b>692.47</b>	<b>738.97</b>	<b>988.00</b>
<b>4</b> Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
<b>5</b> Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	<b>308.14</b>	<b>276.76</b>	<b>347.77</b>	<b>801.83</b>	<b>974.71</b>	<b>1,277.44</b>	<b>211.09</b>	<b>268.29</b>	<b>387.70</b>	<b>692.47</b>	<b>738.97</b>	<b>988.00</b>
<b>6</b> Tax Expenses												
Current Year	64.36	68.23	102.57	189.55	291.38	363.94	64.36	68.23	102.57	189.55	291.38	363.95
MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liability	(15.66)	(12.03)	(7.07)	(31.37)	(21.61)	(31.25)	(16.74)	(11.37)	(7.07)	(32.02)	(21.61)	(31.52)
<b>Total Tax Expense</b>	<b>48.69</b>	<b>56.21</b>	<b>95.50</b>	<b>158.18</b>	<b>269.77</b>	<b>332.69</b>	<b>47.62</b>	<b>56.86</b>	<b>95.50</b>	<b>157.53</b>	<b>269.77</b>	<b>332.43</b>
<b>7</b> Net Profit /Loss for the period from Continuing operation (5- 6)	<b>259.44</b>	<b>220.55</b>	<b>252.27</b>	<b>643.65</b>	<b>704.94</b>	<b>944.75</b>	<b>163.47</b>	<b>211.43</b>	<b>292.20</b>	<b>534.95</b>	<b>469.20</b>	<b>655.57</b>

*R. Bishnoi*



Particulars	Standalone						Consolidated					
	Three Month period Ended			Half Year Ended		Year Ended	Three Month period Ended			Half Year Ended		Year Ended
	31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 Audited	31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 Audited
8 Other Comprehensive Income Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	259.44	220.55	252.27	643.65	704.94	944.75	163.47	211.43	292.20	534.94	469.20	655.57
10 Net Profit /Loss attributable to a) Controlling Interest b) Non-controlling Interest							218.72 (55.25)	266.68 (55.25)	347.45 (55.25)	590.29 (55.25)	524.45 (55.25)	710.82 (55.25)
10 Paid up equity share capital (Rs. 10/- per share)	1,356.28	1,356.28	1,271.46	1,356.28	1,271.46	1,271.46	1,356.28	1,356.28	1,271.46	1,356.23	1,271.46	1,271.46
11 Earning Per Share (Rs.) Basic	1.91	1.63	1.98	4.75	5.54	7.43	1.21	1.56	2.30	3.94	3.69	5.16
Diluted	1.91	1.63	1.98	4.75	5.54	7.43	1.21	1.56	2.30	3.94	3.69	5.16

**NOTES :**

- The unaudited financial results for the quarter ended on 31.12.2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13th February, 2026
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi  
Dated : 13.02.2026

For & on behalf of Board of Directors  
Medicamen Biotech Limited

*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman



LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED FOR THE QUARTER ENDED 31 DECEMBER 2025 AND YEAR TO DATE RESULTS FOR THE PERIOD FROM 01 APRIL 2025 TO 31 DECEMBER 2025 PURSUANT TO REGULATION 33 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To

The Board of Directors,  
Medicamen Biotech Ltd.  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and nine months ended on December 31, 2025 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
Chartered Accountants



Rai Qimat  
Partner

(Membership Number: 013152C)  
UDIN : 26080857QLXLXA7396

Place: Gurugram  
Date: 13.02.2026

LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED FOR THE QUARTER ENDED 31 DECEMBER 2025 AND YEAR TO DATE RESULTS FOR THE PERIOD FROM 01 APRIL 2025 TO 31 DECEMBER 2025 PURSUANT TO REGULATION 33 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To

The Board of Directors,  
Medicamen Biotech Ltd.  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019

We have reviewed the accompanying Statement of unaudited consolidated financial results of Medicamen Biotech Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its subsidiaries for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited (the "Subsidiary" Company)

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Statements includes the Group's share of net profit/(loss) after tax of Rs. (95.97) Lakhs for the quarter ended on December 31, 2025, as considered in the consolidated unaudited financial results, in respect of its subsidiaries, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

A wholly owned subsidiary M/s Opal Pharmaceuticals Pty Ltd located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditor under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the reports of other auditor and the conversion adjustments prepared by the management of the Parent and reviewed by us.

Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates  
Chartered Accountants



(Membership Number: 013152C)

UDIN : 26080857CSSXEF2544

Place: Gurugram

Date: 13.02.2026